Financial Performance - Royalty Pharma's Portfolio Receipts increased by 20% year-over-year to $727 million in Q2 2025[8, 28] - Royalty Receipts grew by 11% year-over-year to $672 million in Q2 2025[8, 28] - The company repurchased 8 million shares for $277 million in Q2 2025, bringing the total for H1 2025 to $1 billion (31 million shares)[8] - Adjusted EBITDA was $633 million, representing 87.1% of Portfolio Receipts in Q2 2025[28] - Portfolio Cash Flow was $641 million, representing 88.2% of Portfolio Receipts in Q2 2025[28] Capital Allocation and Guidance - Capital Deployment totaled $595 million in Q2 2025[8, 28] - Full year 2025 Portfolio Receipts guidance is $3,050 million to $3,150 million, excluding future transactions, representing approximately 9% to 12% growth[8, 35] - Operating and professional costs are expected to be approximately 9% to 9.5% of Portfolio Receipts for FY 2025[8, 35] Revolution Medicines Partnership - Royalty Pharma entered into a funding partnership with Revolution Medicines for up to $2 billion[15, 16] - This includes up to $1.25 billion for a royalty on daraxonrasib and up to $750 million in senior secured debt[18] - The company projects multi-blockbuster sales potential and an IRR in the teens for daraxonrasib[18]

Q2 2025 Investor Presentation Additional Information and Where to Find It MasterBrand intends to file with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement"), which will include a joint proxy statement of MasterBrand and American Woodmark that will also constitute a prospectus of MasterBrand. Each of MasterBrand and American Woodmark may also file other relevant documents with the SEC regarding the transaction. This presentation is not a s ...

Second Quarter 2025 August 6, 2025 EARNINGS CONFERENCE CALL © 2024 Forward-Looking Statements & Non-GAAP Disclaimer Forward-Looking Statements This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning the Company's plans, goals, objectives, outlook, expectations, and intentions, including statements that are ...

August 6, 2025 Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Terms such as "aim," "anticipate," "believe," "confidence," "contemplate," "continue," "conviction," "could," "drive," "estimate," "expect," "forecast," "future," "goal," "guidance," "intend," " ...

These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the Company's forward-looking statements. These risks and uncertainties include, but are not limited to: consumer reaction to public health and food safety issues; increases in labor costs and fluctuations in the availability of and our ability to attract, train and retain employees; increases ...

Q2 2025 Earnings Presentation 08.06.2025 Learn more at fortrea.com. ©2025 Fortrea Inc. All rights reserved. Fortrea Q2'2025 Earnings presentation FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements Disclosure. Certain information in this presentation contains "forward-looking" statements. You should not place undue reliance on these statements. Forward-looking statements include information concerning our possible or assumed future results of operations, including description ...

Financial Performance - Net sales reached $1615 million in Q2 2025, a year-over-year increase of $61 million [7] - Adjusted EBITDA was $253 million in Q2 2025, up $46 million compared to Q2 2024 [7] - The company reported a net loss of $381 million in Q2 2025, compared to a net income of $60 million in Q2 2024 [7] - Adjusted EPS was $058 in Q2 2025, compared to $038 in Q2 2024 [7] - Free cash flow was $50 million in Q2 2025, a significant increase of $743 million compared to Q2 2024's negative $693 million [7] Segment Performance - TSS (Thermal & Specialized Solutions) net sales increased to $597 million in Q2 2025 [15] - TT (Titanium Technologies) net sales decreased to $657 million in Q2 2025 [15] - APM (Advanced Performance Materials) net sales slightly increased to $346 million in Q2 2025 [15] Strategic Initiatives and Outlook - Opteon Refrigerants in TSS achieved 65% year-over-year net sales growth [6] - The company announced a settlement with the State of New Jersey to resolve environmental claims, with Chemours' discounted share of settlement payments being approximately $250 million [6, 27] - Q3 2025 net sales are expected to decline 4-6% sequentially, with adjusted EBITDA between $175-$195 million [40, 41] - Full year 2025 adjusted EBITDA is projected to be between $775 million and $825 million, with net sales between $59 billion and $60 billion [44]

Q2'25 Financial Performance - Trimble's Q2'25 as-adjusted revenue reached $876 million, reflecting a 9% organic growth compared to Q2'24[17] - The company's ARR (Annual Recurring Revenue) stood at $2,210 million, demonstrating a 14% organic increase year-over-year[13, 17] - Non-GAAP Gross Margin improved to 706%, a 210 bps increase from 685% in Q2'24[17] - Non-GAAP Operating Income Margin also saw a 210 bps rise, reaching 254% compared to 233% in the previous year[17] - Adjusted EBITDA Margin expanded by 170 bps to 274% from 257% in Q2'24[17] Segment Performance - AECO (Architects, Engineers, Construction, Owners) segment revenue was $350 million, with a 16% organic growth[23] and ARR of $1,360 million, also up by 16% organically[23] - Field Systems segment revenue reached $393 million, showing a 3% organic increase[26], and ARR grew by 17% organically to $358 million[26] - Transportation & Logistics (T&L) segment revenue was $133 million, reflecting an 8% organic growth[30], with ARR at $492 million, also up by 8% organically[30] FY'25 Outlook - The company updated its FY'25 revenue guidance to $346 to $354 billion, an increase of $100 million at the midpoint[34] - Organic revenue growth for FY'25 is projected to be between 6% and 9%[34]

Financial Performance - Total revenue increased by 09% to $1350 million[3] - Adjusted EBITDA decreased by 24% to $326 million[3] - Adjusted EBITDA margin decreased by 90 bps to 241%[3] - AFFO increased 551% to $211 million[3] - AFFO per share increased 80% to $081[3] - GAAP net loss of $(7) million, or $(003) per diluted common share[3] Guidance - Full-year 2025 adjusted EBITDA is now expected to be $129 to $134 billion, revised down from the prior guidance of $135 to $140 billion[5] - Adjusted FFO per share for full-year 2025 is expected to be $320 to $340, revised down from the prior guidance of $340 to $360[5] - Third-quarter 2025 adjusted EBITDA is expected to be $326 to $336 million[5] - Third-quarter 2025 AFFO per share is expected to be $075 to $079[5]

Investor Presentation FY26 Q1 June 2025 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend ...